In a study of 42 obese patients with type 2 diabetes, amlexanox treatment administered as 50 mg tablets three times per day for 12 weeks resulted in a reduction of haemoglobin A1c levels and in a subgroup improved insulin sensitivity and hepatic steatosis.12 Here, INS is linked to fatty liver disease.